stella
beta
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC — Stella
Recruiting
Back to Resectable NSCLC trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(3 sites)
China
Peking Union Medical College Hospital, Beijing
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
The First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang
View full record on ClinicalTrials.gov